---
title: "Transocean (RIG) Revenue Surges 15%, ADC Therapeutics (ADCT) Down 3.92%"
canonical_url: https://www.stockexpertai.com/journal/2026-05-05/transocean-rig-revenue-surges-15-adc-therapeutics-adct-down-392
last_updated: 2026-05-05T06:18:24.160Z
section: "Earnings Watch"
author: "Taylor Brooks"
publisher: Stock Expert AI
tickers: RIG, ADCT, AMRC, ADUS, BWIN, NVTS, VVX, MATX
content_type: journal-article
---

# Transocean (RIG) Revenue Surges 15%, ADC Therapeutics (ADCT) Down 3.92%

## The Take
- Investors should analyze key metrics and year-over-year comparisons to assess company performance and sector trends during this earnings season.

_Earnings season continues with key metrics under scrutiny for RIG, ADCT, AMRC, ADUS, and BWIN. Mixed results reflect varied sector health._

Earnings season brings clarity—and volatility. Several companies have recently reported their Q1 2026 earnings, providing insights into their performance and the broader market. Investors are closely monitoring these reports to gauge the overall health of the market and individual companies. Transocean (RIG) stands out with a 15% year-over-year revenue increase, reaching $1.2 billion and surpassing expectations. This reflects a recovery in offshore drilling demand, with earnings per share at $0.25, above the anticipated $0.20. 

In the healthcare sector, ADC Therapeutics (ADCT) reported a 3.92% decrease, with first quarter 2026 net product revenues of $20 million, a 15% increase from the previous year. The company reduced operating expenses by 13% compared to Q1 2025, maintaining a healthy cash balance. Management is optimistic about Zenlonta's potential, projecting peak annual revenues between $600 million and $1 billion in the US. Addus HomeCare (ADUS) also released its Q1 earnings, with analysts focusing on how key metrics align with market expectations. 

Ameresco (AMRC) also reported Q1 earnings; the focus is on comparing key performance indicators against Wall Street estimates and year-ago figures. Similarly, The Baldwin Insurance Group (BWIN) earnings are under analysis, with attention on revenue and EPS compared to estimates. These analyses are crucial for determining the overall financial health of these companies. Meanwhile, NVTS is heading into its Q1 earnings report with expectations of a steep decline in revenue.

VVX's management has provided positive earnings guidance for the remainder of 2026, anticipating continued growth in key sectors. Matson's performance highlights the importance of analyzing both earnings and sales figures to get a complete view of a company's financial health. Expectations are set. Now comes execution.

## Related Tickers
- [RIG](https://www.stockexpertai.com/stock/rig)
- [ADCT](https://www.stockexpertai.com/stock/adct)
- [AMRC](https://www.stockexpertai.com/stock/amrc)
- [ADUS](https://www.stockexpertai.com/stock/adus)
- [BWIN](https://www.stockexpertai.com/stock/bwin)
- [NVTS](https://www.stockexpertai.com/stock/nvts)
- [VVX](https://www.stockexpertai.com/stock/vvx)
- [MATX](https://www.stockexpertai.com/stock/matx)

## Frequently Asked Questions

### What drove Transocean's (RIG) revenue increase?
Transocean's 15% revenue surge to $1.2 billion reflects a recovery in offshore drilling demand. The company's earnings per share also exceeded expectations, indicating strong performance in a recovering market. Investors are closely watching the company's performance as the energy sector evolves.

### How did ADC Therapeutics (ADCT) perform in Q1 2026?
ADC Therapeutics (ADCT) reported a 3.92% decrease in revenue, with net product revenues of $20 million. While this represents a decrease, the company managed to reduce operating expenses and maintain a healthy cash balance. Management is optimistic about the future potential of Zenlonta.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._